NCT00233649已完成不适用
DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 2,500
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to determine in DM II patients the efficacy of Crestor in obtaining the new European LDL cholesterol guidelines.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diabetes Mellitus Type 2, LDL-C > 2,5 mmol/l, no cholesterol lowering medication used last 3 months, starts with Crestor 10 mg, permission to use patient data by AZ
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active ComparatorType 2 Diabetes MellitusNCT00760578Metabolic Solutions Development Company86
已完成
3 期
Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes SubjectsNon-alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2NCT02242149Universidade Federal do Rio de Janeiro84
已完成
3 期
Diamel in the Treatment of Type 2 Diabetic Patients Receiving Insulin TherapyType 2 DiabetesNCT00994266Catalysis SL116
已完成
2 期
The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive SubjectsObesityInsulin ResistanceNCT00146289Boehringer Ingelheim138
已完成
不适用
Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2Type 2 Diabetes MellitusNCT01065298Post Graduate Institute of Medical Education and Research, Chandigarh30